Spidroin-SpyTag Hydrogel for Injectable Sustained CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for stimulating CNS axon regeneration in humans are ineffective due to the short half-life of signaling molecules and the limitations of viral delivery systems, and existing hydrogels lack biocompatibility, mechanical properties, and ease of manufacture for therapeutic delivery.
Innovation Solution
A recombinant spider silk protein-based hydrogel (spidroin-SpyTag) that undergoes a rapid sol-gel transition for injectable delivery of bioactive agents like CNTF, IGF1, and laminin, utilizing SpyTag/SpyCatcher click chemistry for functionalization and sustained release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If viral delivery systems are used to deliver signaling molecules, then extended in vivo delivery is achieved, but cost, complexity, safety, and scalability concerns arise
Solution Approach 1:
The patent changes the physical-chemical parameters of the delivery system by using hydrogel phase transition (sol-gel transition) instead of viral vectors. The hydrogel transitions from soluble to gel state in response to physiological conditions, providing sustained delivery without the complexity of viral systems
Solution Approach 2:
The patent replaces expensive, complex viral delivery systems with a simpler, more scalable hydrogel-based system that can be manufactured more easily and safely, while achieving comparable or superior sustained delivery performance
2Duration of action of moving object
If synthetic hydrogels are used for drug release, then controlled release properties are achieved, but harsh gelation conditions and toxic by-products are generated
Solution Approach 1:
The patent uses a composite hydrogel system combining natural polymer components (collagen, hyaluronic acid) with synthetic crosslinking mechanisms, achieving controlled release properties while maintaining biocompatibility and avoiding toxic by-products
Solution Approach 2:
The patent modifies the gelation conditions by using physiological pH and temperature-triggered gelation instead of harsh chemical conditions, enabling controlled drug release without generating toxic by-products
3Reliability
If naturally derived polymers like collagen and gelatin are used, then biocompatibility is achieved, but poor mechanical properties and pathogen transmission risk arise
Solution Approach 1:
The patent creates composite hydrogels combining natural polymers (collagen, hyaluronic acid) with carefully selected synthetic components that enhance mechanical strength while maintaining biocompatibility and eliminating pathogen transmission risks through controlled manufacturing
Solution Approach 2:
The patent uses recombinant spidroin protein as a safe, scalable alternative to natural silk, producing a biocompatible material with improved mechanical properties that eliminates pathogen transmission risks associated with natural polymer extraction
4Reliability
If signaling molecules are delivered for CNS axon regeneration, then axon regeneration is promoted, but short half-life limits clinical application
Solution Approach 1:
The patent implements continuous sustained release of signaling molecules from the hydrogel matrix, maintaining therapeutic concentrations over extended periods to match the slow timescale of CNS axon regeneration, thereby overcoming the short half-life limitation
Solution Approach 2:
The patent pre-loads the hydrogel with signaling molecules (CNTF, IGF1, NT-3) before implantation, ensuring immediate and sustained availability of these therapeutics at the injury site without requiring repeated administrations
5Ease of operation
If an injectable hydrogel is designed for in situ delivery, then minimally invasive administration is achieved, but rapid sol-gel transition in vivo is difficult to achieve with existing materials
Solution Approach 1:
The patent designs hydrogels that undergo rapid sol-gel transition in response to physiological parameters (pH, temperature) upon injection, enabling minimally invasive delivery while achieving immediate gel formation and drug release at the target site
Solution Approach 2:
The patent replaces complex mechanical injection systems with chemically-triggered sol-gel transition that occurs automatically upon contact with physiological conditions, simplifying the delivery mechanism while maintaining minimally invasive characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The spidroin-SpyTag hydrogel provides a safe, minimally invasive, and sustained delivery system for promoting neuroprotection and axon regeneration in CNS disorders, demonstrating enhanced bioactivity and biocompatibility.
Implementation Method 1
spidroin-SpyTag undergoes a rapid sol-gel transition for injectable delivery
Implementation Method 2
utilizing SpyTag/SpyCatcher click chemistry for functionalization
Implementation Method 3
sustained release
Implementation Method 4
sustained release
Data Source
AI summary
The subject invention pertains to a novel injectable protein delivery system and methods for delivering one or more therapeutic agents in the central nervous system (CNS) for promoting axon regeneration. This system is based on the use of a recombinant spider silk protein called spidroin-SpyTag, which undergoes a rapid transition from a sol state to a gel state when exposed to ultrasound treatment and incubated at body temperature. This unique characteristic allows the easy injection of the material into a specific target tissue. The methods herein disclosed allow the delivery of protein therapeutics covalently conjugated to the spidroin-SpyTag to a subject affected by a CNS disorder of injury. Additionally, the method for fabricating this injectable protein delivery system is rapid, convenient, and cost-efficient.